WT1 and acute myeloid leukemia: Among a cohort of 129 AML patients, a WT1 reduction below 200 copies after the first induction chemotherapy was associated with a longer duration of CR, independently from age, WBC count or cytogenetic risk group.10 Based on the post induction WT1 level, Nomdedeu et al.37 identified three prognostic AML groups: group 0 (no. ofWT1 copies 0–17.5, in 134 patients), group 1 (no. ofWT1 copies 17.6–170.5, in 160 patients), and group 3 (no. of WT1 copies >170.5, in 71 patients).